CYP3A4-mediated Pharmacokinetic Interactions in Cancer Therapy

Author(s): Dandan Tian, Zheyi Hu

Journal Name: Current Drug Metabolism

Volume 15 , Issue 8 , 2014

Become EABM
Become Reviewer


Cytochromes P450 enzymes, especially CYP3A4, are responsible for metabolizing a broad range of anticancer drugs. Combination therapy is common in patients with cancer, which may cause potential drug drug interactions (DDIs) leading to increased risk of side-effects/toxicity or decreased effectiveness. The review summarizes CYP3A4-mediated DDIs, with anticancer drugs as CYP3A4 substrates or modulators, in clinical trials during cancer therapy and aims to increase clinicians' awareness to take caution to reduce the risk.

Keywords: Anticancer drugs, cytochromes P450 (CYP) enzymes, drug-drug interactions, pharmacokinetics.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 25 February, 2015
Page: [808 - 817]
Pages: 10
DOI: 10.2174/1389200216666150223152627
Price: $65

Article Metrics

PDF: 77